MEK inhibitors for the treatment of non-small cell lung cancer

MEK inhibitors for the treatment of non-small cell lung cancer

Abstract BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RA...

Full description

Bibliographic Details
Main Authors: Jing Han, Yang Liu, Sen Yang, Xuan Wu, Hongle Li, Qiming Wang
Format: Article
Language:English
Published: BMC 2021-01-01
Series:Journal of Hematology & Oncology
Subjects:
Non-small cell lung cancer
MEK inhibitors
Targeted therapy
RAS
RAF
MEK
Online Access:https://doi.org/10.1186/s13045-020-01025-7

Internet

https://doi.org/10.1186/s13045-020-01025-7

Similar Items